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INTRODUCTION
Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are released from the heart in response to increased cardiac volume ). Acutely, they increase renal fluid secretion and arterial vasodilation. Chronically, they inhibit cardiac hypertrophy. The signaling receptor for ANP and BNP is guanylyl cyclase-A (GC-A), also known as natriuretic peptide receptor-A. C-type natriuretic peptide (CNP) activation of guanylyl cyclase-B (GC-B), also known as natriuretic peptide receptor-B, preferentially dilates veins as opposed to arteries (Wei et al., 1993) , and like GC-A, inhibits cardiac hypertrophy (Langenickel et al., 2006) . Both GC-A and GC-B are transmembrane guanylyl cyclases that catalyze the synthesis of cGMP upon ligand binding. The third natriuretic peptide receptor, natriuretic peptide receptor C (NPR-C), binds all three natriuretic peptides with similar affinity and clears them from the circulation through receptor-mediated endocytosis degradation.
BNP has been extensively studied as a potential therapeutic for the treatment of congestive heart failure and renal diseases (Boerrigter et al., 2009 ). The U.S. Food and Drug Administration approved recombinant BNP (nesiritide) for the treatment of acutely decompensated heart failure in 2001. However, subsequent reports indicated that hypotension-dependent reductions in renal perfusion pressures ultimately decrease renal fluid loss, which limits the use of nesiritide in the treatment of heart failure (Sackner-Bernstein et al., 2005) . Thus, natriuretic peptides with reduced hypotensive actions but maintained renal actions may be superior to nesiritide.
One approach to producing more therapeutic natriuretic peptides is to create chimeric molecules that activate both guanylyl cyclase receptors. GC-A mediates the renal affects of ANP and This article has not been copyedited and formatted. The final version may differ from this version. BNP(Kishimoto et al., 1996) , whereas GC-B mediates the venodilation effect of CNP but does not activate the kidney. Additionally, unlike GC-A, cardiac GC-B is not downregulated in response to congestive heart failure . Thus, our rationale was to produce peptides with reduced affinity for GC-A but increased affinity for GC-B in order to decrease cardiac preload and hypertrophy observed in heart failure. BNP was used as the starting backbone for the chimeric peptides due to its increased half-life (~20 min vs. 1-2 min for ANP and CNP). Residues in the 17-amino acid disulfide ring of BNP were substituted in order to modulate receptor-binding affinity (Fig. 1) . Eleven of the 17 residues are identical between human ANP, BNP and CNP, which leaves only two unique triad sequences as potential regulators of binding specificity (Fig. 1) . Here, we describe the effects of two single amino acid substitutions -individually or in combination -on the ability of BNP to activate human GC-A and GC-B or bind NPR-C. We found that a single substitution in the first divergent triad region markedly and reciprocally modulates GC-A and GC-B activation while substitutions in the second triad were ineffective. This article has not been copyedited and formatted. The final version may differ from this version. Cells. Human embryonic kidney 293 cells stably expressing human GC-A or GC-B were cultured as previously described (Dickey et al., 2008) .
Whole cell cGMP assays. Cells plated in 48-well plates were incubated in serum-free medium for 4 hrs. The cells were pretreated for 10 min at 37°C in DMEM containing 25mM HEPES, pH 7.4 and 1mM 1-methyl-3-isobutylxanthine (IBMX) after aspiration of the starvation medium.
After pretreatment, the medium was replaced with the same medium containing various concentrations of natriuretic peptides. The cells were stimulated for 3 min and then the assay was terminated by aspiration and the addition of 0.2 ml ice-cold 80% ethanol. Cyclic GMP concentrations were estimated by radioimmunoassay as previously described ).
Membrane guanylyl cyclase assays. Crude membranes were prepared as previously described . Twenty μl membranes were assayed for 3 min at 37°C containing 1 mM Mg-GTP in the presence or absence of various concentrations of natriuretic peptide as previously described ). The assayed were stopped with the addition of 0.4 ml cold 50
This article has not been copyedited and formatted. The final version may differ from this version. mM sodium acetate buffer containing 5 mM EDTA and placed on ice. An aliquot was assayed for cGMP using a cGMP radioimmunoassay kit from Perkin Elmer.
Whole cell binding assays. Cells were plated on 24-well plates precoated with polylysine. When the cells were 75-90% confluent, the growth media was replaced with 0.2% BSA in DMEM for 1-2 h. Binding media containing 1% BSA and 125 I-ANP was prepared on ice. Binding media containing increasing concentrations of unlabelled ligand were added to the cells and incubated at 4°C for 1 h. The cells were washed with ice-cold PBS to remove non-specific bound tracer.
0.5 ml of 1N NaOH was added to solubilize the cells. The cell extracts were counted in a
Beckman gamma 5500 counter.
Statistics. The whole cell experiment was performed in triplicate in three separate assays.
Concentrations required to achieve 50% of the maximum effect (EC 50 ) were calculated with Prism software using a Sigmoidal dose response curve fit. Differences between treatments was determined by paired t test where p < 0.05 was considered significant. The graphs of the guanylyl cyclase assays were from two separate assays of two individual samples assayed in duplicate. The binding experiment graphs represent three (GC-A) or two (NPR-C) separate experiments assayed in triplicate. Dissociation constants for 125 I-ANP binding were calculated using Prism software using a one-site competition model. Differences between treatments were determined by paired t test (GC-A) or an F test (NPR-C) where p < 0.05 was considered significant.
This article has not been copyedited and formatted. The final version may differ from this version. 
RESULTS
The goal of this study was to create derivatives of BNP with reduced potency for GC-A and improved potency for GC-B. All natriuretic peptides contain an amino-terminal region followed by a 17-amino acid disulfide ring (Fig. 1) . Of the 17 residues within the ring, eleven are identical (shaded residues in Fig. 1 ). Since CNP binds a different receptor than ANP or BNP, identical residues between CNP or ANP and BNP cannot determine binding specificity. Previous studies from our group suggested that triple substitutions in one of the two variable regions in the 17-amino acid ring of a C-terminally extended form of CNP called CD-NP, modified the binding preference for GC-A and GC-B (Dickey et al., 2008) . Here, we investigated the effect of single or double substitutions on the ability of BNP to activate GC-A and GC-B.
The first unique triad consists of RKM and LKL in BNP and CNP, respectively. Since the middle K is conserved in both peptides, we mutated the first amino acid of this triad from an R to an L in BNP and called it L-BNP. The second triad sequence is SSS in BNP and GSM in CNP, respectively. The first residue (G) in the second CNP triplet is unlikely to cause any changes in receptor affinity since it is also a G in ANP, another GC-A agonist. The second residue in the triplet is an S, which is identical between BNP and CNP. Therefore, the third amino acid in the first BNP triplet was the sole focus for substitution analysis of this region because it is the only one that significantly varies between peptides that activate either GC-A or GC-B. We substituted the third S in BNP with an M from CNP to make M-BNP. A derivative peptide containing both amino acid substitutions called LM-BNP was also examined.
This article has not been copyedited and formatted. The final version may differ from this version. was not statistically different from the wild-type BNP. These data indicate that the changes in GG-A and GC-B activation result from changes in the affinity of the peptides for the receptors.
Effect on NPR-C binding. BNP is primarily removed from the circulation by NPR-C mediated internalization and degradation. The clearance receptor binds all three natriuretic peptides similarly. However, BNP has been shown to bind about 10-fold less tightly to NPR-C, which may contribute to the increased half-life of BNP compared to ANP and CNP (Suga et al., 1992) .
To directly measure the affinity of each peptide to NPR-C, the ability of the wild type or mutant These data are related to previous results from our group on the activation of GC-A and GC-B by CD-NP (Dickey et al., 2008) . CD-NP is designer natriuretic peptide consisting of the 15-residue carboxyl-terminus of dendroaspis natriuretic peptide appended to carboxyl-terminus of CNP (Lisy et al., 2008) (Fig. 1) . In a recent clinical trial, CD-NP demonstrated natriuretic and aldosterone-suppressing properties without inducing excessive hypotension (Lee et al., 2009 ).
We found that CD-NP bound GC-A tighter than CNP, which indicates that the carboxyl-terminal extension increases the affinity of CNP to human GC-A. Additional studies investigated the effect of substituting all three amino acids from the first variable region of BNP into CD-NP This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 1) . We found that substitution of RKL from BNP for LKL in CNP converted CD-NP into a potent GC-A agonist. In fact, this peptide was more potent and bound GC-A more tightly than wild type BNP. In contrast, the substitution of SSS from BNP for GSM in CNP in the second variable triad only slightly increased the affinity and potency of CD-NP for GC-A. As for L-BNP, reciprocal reductions in the potency of the mutant CD-NP peptides for GC-B were also observed. However, although the mutation in the second triad only slightly decreased potency for GC-A, it dramatically decreased potency for GC-B.
The data presented here are also consistent with a previous report by Furuya and colleagues who found the replacing the LKL region with the analogous triad from ANP (GRM), markedly reduced CNP-dependent cGMP elevations in rat smooth muscle cells (Furuya et al., 1992) . They also found that individual substitutions in the second triad had little effect on rat GC-B activation, which is consistent with our results showing that the EC 50 for activation of human GC-B by BNP and M-BNP are similar.
In summary, we have identified a single mutation in BNP that differentially regulates binding and activation of GC-A and GC-B without affecting binding to NPR-C. Future studies will focus on the effect of this mutation on the half-life of the peptide.
